Evidence map›Paper›PMID 39844043›Full record

ArticleClinical proteomics2025

Integrating functional proteomics and next generation sequencing reveals potential therapeutic targets for Taiwanese breast cancer.

Wei-Chi Ku, Chih-Yi Liu, Chi-Jung Huang, Chen-Chung Liao, Yen-Chun Huang, Po-Hsin Kong, Hsieh Chen-Chan, Ling-Ming Tseng, Chi-Cheng Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei-Chi Ku *School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, 242, Taiwan.
Chih-Yi Liu *School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, 242, Taiwan.
Chi-Jung HuangDepartment of Medical Research, Cathay General Hospital, Taipei, 106, Taiwan.
Chen-Chung LiaoCancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
Yen-Chun HuangMarker Exploration Corporation, Taipei, 112, Taiwan.
Po-Hsin KongMarker Exploration Corporation, Taipei, 112, Taiwan.
Hsieh Chen-ChanMarker Exploration Corporation, Taipei, 112, Taiwan.
Ling-Ming TsengDivision of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan. lmtseng87@gmail.com.
Chi-Cheng HuangDivision of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan. chishenh74@gmail.com.

Funding

Fu-Jen Catholic University PL-201812001-TMinistry of Health and Welfare MOHW111-TDU-B-222-124016, MOHW112-TDU-B-222-124016, MOHW113-TDU-B-222-124016National Science and Technology Council NSTC 111-2314-B-075-063-MY3Taipei Veterans General Hospital V110E-005-3, V111E-006-3, V112E-004-3 and V112C-013
6 · The paper itself

Abstract

Integrating functional proteomics and next-generation sequencing (NGS) offers a comprehensive approach to unraveling the molecular intricacies of breast cancer. This study investigates the functional interplay between genomic alterations and protein expression in Taiwanese breast cancer patients. By analyzing 61 breast cancer samples using tandem mass tag (TMT) labeling and mass spectrometry, coupled with whole-exome sequencing (WES) or targeted sequencing, we identified key genetic mutations and their impact on protein expression. Notably, pathogenic variants in BRCA1, BRCA2, PTEN, and PIK3CA were found to be clinically relevant, potentially guiding targeted therapy decisions. Additionally, we discovered trans correlations between specific gene alterations (FANCA, HRAS, PIK3CA, MAP2K1, JAK2) and the expression of 22 proteins, suggesting potential molecular mechanisms underlying breast cancer development and progression. These findings highlight the power of integrating proteomics and NGS to identify potential therapeutic targets and enhance personalized medicine strategies for Taiwanese breast cancer patients.

Indexed as

Functional proteomicsNext-generation sequencingTaiwanese breast cancerTargeted sequencingWhole exome sequencing

Identifiers

PMID39844043
PMCPMC11753163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.